Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 1

Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

NCT ID: NCT06191133Sponsor: Lindsay Ferguson, MDLast updated: 2025-10-02

Summary

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

Arms & interventions

  • DrugFenofibrate

    Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.

  • ProcedureCervical Conization

    Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix

  • ProcedureHysterectomy

    In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.

  • RadiationChemoradiation

    Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.

Outcome measures

Primary

  • Change in p53 levels

    Changes in p53 levels from initial biopsy to repeat sampling at the time of surgery

    Time frame: Up to six weeks after study enrollment

  • Change in tumor metabolic status

    Changes in tumor metabolic status from initial biopsy to repeat sampling at the time of surgery evaluated via immunohistochemical testing

    Time frame: Up to six weeks after study enrollment

Secondary

  • Fenofibrate tolerability

    Time frame: Up to six weeks after study enrollment

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Participants must have histologically or cytologic confirmed high grade dysplasia or cervical cancer. Histologic types include squamous cell, adenocarcinoma or adenosquamous cell carcinoma. * Participants must be eligible for surgical management with LEEP, CKC or hysterectomy or chemoradiation * Age ≥ 18 years * Normal liver function (AST, ALT, bilirubin within institutional normal limits). * Participants must be English speaking * Participants must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants with active liver disease, including primary biliary cirrhosis and unexplained, liver function abnormality * Participants with severe kidney impairment (CrCl ≤30 mL/min calculated using Cockcroft-Gault), or end-stage kidney disease on dialysis * Participants with preexisting gallbladder disease including active gallstones * Known hypersensitivity to fenofibrate or fenofibric acid * Participants that are pregnant or breast feeding due to unknown risk to developing fetus/infant. Please note: Participants of child-bearing potential (have had menses within the past year or have not had total hysterectomy) are actively screened for pregnancy prior to diagnostic procedures and screened again prior to treatment.

Study locations (1)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Cleveland, Ohio, 44106

Recruiting
Lindsay A Ferguson, MD · Contact
216-844-3954lindsay.ferguson@uhhospitals.org
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | Cancerify